Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe
Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co. Ltd., and Swixx BioPharma AG today announced that the Croatian National Health Insurance Fund (NHIF) and the Bulgarian Ministry of Health have both approved the reimbursement of POTELIGEO ® (mogamulizumab) for adult patients with mycosis fungoides (MF), and Sézary syndrome (SS).
MF and SS are two subtypes of cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin's lymphoma that presents and persists in the skin and can cause debilitating physical, emotional and social challenges. 1 MF—the most common CTCL subtype—accounts for approximately 60% of all CTCLs. 2
With an average time to diagnosis of 3-4 years, MF is typically characterised by skin symptoms including patches or plaques, skin redness and tumours. 3,4 SS is much rarer, accounting for around 5% of CTCLs, 5 and is more aggressive, causing severe itching, erythroderma, intense scaling of the skin and frequent hair loss. 6
Jeremy Morgan, President of Kyowa Kirin International, commented: 'I am delighted that the Croatian and Bulgarian authorities have agreed to reimburse POTELIGEO for MF and SS patients. Both decisions are important milestones for people impacted by these rare and challenging forms of CTCL, and with mogamulizumab now reimbursed in more than 20 countries across the EMEA region we remain as committed as ever to delivering life changing value for people impacted by under-diagnosed and under-served diseases, and making more people smile.'
Poteligeo is distributed in Central and Eastern Europe by Swixx, on behalf of KKI. The two companies signed a Promotion and Distribution Agreement in October 2022. Under the terms of the agreement, Swixx will exclusively market, promote and distribute mogamulizumab in both Croatia and Bulgaria, among other countries.
'At Swixx, our mission is to unlock access to innovative medicines, and the recent reimbursement approvals in Croatia and Bulgaria mark significant progress in improving therapeutic options for patients with MF and SS in those markets,' said Dezso Martha, Chief Operating Officer of Swixx. 'We will continue working closely with health authorities, the scientific community, and Kyowa Kirin to expand access to this important medicine, ensuring better outcomes for patients across our Central and Eastern European countries.'
With Croatian reimbursement effective as of 15 th November 2024, and Bulgaria's Ministry of Health confirming reimbursement as of 2 nd January 2025, both decisions build on the inclusion of POTELIGEO ® (mogamulizumab) in the Polish Ministry of Health's Drug Programme announced in July 2024 and the ongoing expansion of access to patients across Central and Eastern Europe (CEE).
About Poteligeo (mogamulizumab)
Mogamulizumab is a first-in-class humanised monoclonal antibody directed against CC-chemokine receptor 4 (CCR4), a protein consistently expressed on cancerous cells seen in both MF and SS. 7-9 Once mogamulizumab binds to CCR4, it increases attraction of immune cells from the immune system to destroy the cancerous cells. 10
About MF and SS
MF and SS are two subtypes of CTCL, which is itself a rare form of non-Hodgkin's lymphoma that presents and persists in the skin. 1 CTCL is treatable, but is not generally considered to be curable, and there has been a clear unmet need for novel treatment options. As well as the obvious impact of symptoms upon patients, there can be significant erosions to quality of life for those caring for an individual living with CTCL. 11
MF and SS are characterised by localisation of cancerous white blood cells called T lymphocytes (T cells), to the skin. 12 These cancerous T cells consistently express a protein called CCR4, which enables them to move from the blood to the skin. 7-9 When these cancerous T cells move to the skin, this results in the visible early skin symptoms of red patches or plaques which can resemble psoriasis or eczema in the early stages of the disease. 6 Later, for some patients, skin involvement may evolve to include tumours or reddening of the majority of the skin's surface (erythroderma).
MF—the most common CTCL subtype—accounts for approximately 60% of all CTCLs 2 and is typically indolent, characterised by skin symptoms including patches or plaques, skin redness and tumours. 3,4 SS is much rarer, accounting for around 5% of CTCLs, 5 and is more aggressive, 6 with high levels of blood involvement. 5 It can cause severe itching, erythroderma, intense scaling of the skin and frequent hair loss. 6 CTCL can take, on average, between 2 and 7 years for individuals to receive a confirmed diagnosis. 6
About Kyowa Kirin
Kyowa Kirin aims to discover novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients affected by severe and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across our four regions – Japan, Asia Pacific, North America, and EMEA/International.
You can learn more about the business of Kyowa Kirin at:
About Swixx BioPharma AG
Swixx BioPharma is one of the fastest-growing, largest, intercontinental commercial platforms for the biopharmaceutical industry. Swixx operates subsidiaries across Central and Eastern Europe, Greece, Russia, several Eurasian countries, the Middle East, and via Biopas, a Swixx BioPharma company, in almost 20 Latin American countries. Swixx BioPharma Group has over 1,600 employees and sales likely to exceed a billion Euros in 2024. The company has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and self-medication talent under one roof.
CONTACT: Contacts for Kyowa Kirin Co., Ltd.:
Media
KEYWORD: UNITED KINGDOM SWITZERLAND EUROPE CROATIA BULGARIA
SOURCE: Kyowa Kirin International
Copyright Business Wire 2025.
PUB: 01/30/2025 05:05 AM/DISC: 01/30/2025 05:06 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
4 days ago
- Newsweek
US Launches Major Visa Crackdown
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The U.S. State Department has announced sweeping visa revocations and restrictions targeting several foreign officials. Visa restrictions have been imposed on officials and their family members from several regions—including Brazil, Cuba and Grenada—for their alleged participation in facilitating Cuba's medical mission program. Newsweek has contacted the U.S. State Department for comment via email outside office hours. Why It Matters The latest visa restrictions signal the Trump administration's tougher approach to confronting Cuba's overseas medical mission programs and penalizing governments that participate in or facilitate them. U.S. President Donald Trump's government has deployed hard-line policies toward the communist country. For decades, Cuba has deployed medical personnel to less-developed countries, with the host nations providing payments that contribute to Cuba's foreign currency earnings. According to the U.S. State Department, numerous doctors have reported experiencing exploitation within this arrangement, which involved coordination through the Pan American Health Organization and Brazil's Ministry of Health. The U.S. Department of State in Washington, D.C., on May 2. The U.S. Department of State in Washington, D.C., on May 2. Samuel Corum/Sipa via AP Images What To Know U.S. Secretary of State Marco Rubio said the visas of two former Brazilian health officials, Mozart Julio Tabosa Sales and Alberto Kleiman, had been revoked. These individuals were connected to Brazil's Mais Médicos ("More Doctors") initiative, a program that hosted Cuban medical personnel in remote areas of Brazil during President Dilma Rousseff's administration. "These officials were responsible for or involved in abetting the Cuban regime's coercive labor export scheme, which exploits Cuban medical workers through forced labor. This scheme enriches the corrupt Cuban regime and deprives the Cuban people of essential medical care," Rubio said in a news release on August 13. Tabosa Sales and Kleiman served in Brazil's Ministry of Health during the Rousseff administration, a period when thousands of Cuban medical professionals were deployed to deliver health care services in remote and economically disadvantaged regions of the country. The State Department described Cuba's medical missions as a system that "rented" medical professionals to other nations at high prices, with most of the revenue retained by Cuban authorities. Cuban Deputy Foreign Minister Carlos Fernandez de Cossio pushed back on the allegations put forward by the U.S. State Department. What People Are Saying U.S. Secretary of State Marco Rubio said in a statement: "Dozens of Cuban doctors that served in the program have reported being exploited by the Cuban regime as part of the program." Cuban Deputy Foreign Minister Carlos Fernandez de Cossio wrote on X, translated from Spanish: "Cuba will not abandon its medical service programs in dozens of countries. They are absolutely legitimate and, more importantly, save lives and support communities. The U.S. secretary of state is a dishonest politician, intent on causing harm at the expense of depriving many of health care services." What Happens Next It remains to be seen whether the affected countries, which include African nations, will issue diplomatic responses.
Politico
4 days ago
- Politico
US imposes visa restrictions on Brazilian officials for working with Cuban medical mission
Tabosa Sales and Kleiman worked in Brazil's Ministry of Health under former President Dilma Rousseff, when thousands of Cuban doctors were brought to the country to provide medical care in remote, impoverished areas. The State Department action reflects White House efforts to punish both Cuba and Brazil, which President Donald Trump has sought to pressure over trade and its effort to prosecute former President Jair Bolsonaro for trying to stay in office despite his defeat in the 2022 election. Cuba has for decades sent doctors abroad to provide medical care in less-developed nations in exchange for badly needed hard currency. The State Department said dozens of doctors reported being exploited as part of the program, which was administered through the Pan American Health Organization and Brazil's health ministry. The State Department said it also moved to revoke or restrict the visas of officials in Cuba, Grenada and Africa for involvement with Cuba's overseas medical missions. Cuban officials pointed out the benefits of the programs, highlighting how the country's doctors treated millions of patients in over 3,600 Brazilian municipalities. Cuban Deputy Foreign Minister Carlos Fernandez de Cossio defended its efforts to provide medical care abroad, saying in a social media post that the country's programs 'are absolutely legitimate' and help to alleviate suffering.
New York Post
5 days ago
- New York Post
2 dead, 14 hospitalized after eating tainted sausage and turnip top sandwiches in Italy
Two people died and 14 others, including two teenagers, were hospitalized after eating sausage and turnip top paninis from a food truck in southwest Italy linked to the country's second toxic botulism outbreak in a month. Luigi di Sarno, 52, and Tamara D'Acunto, 45, died within two days of ingesting the tainted sandwiches. Another 14 people were hospitalized with food poisoning, The Telegraph reported. Luigi di Sarno, 52, was sent home from the hospital despite his apparent illness, his sister said. Facebook Advertisement Di Sarno, an artist, was sent home from the hospital even after complaining he wasn't feeling well and later died, his sister told the outlet. All of the victims ate sandwiches from a food truck near the town of Diamante in Calabria, which spans across the toe of Italy's boot, according to authorities investigating the botulism outbreak. They each ordered the same meal: a panini topped with grilled sausage and cime di rapa — or turnip tops in English, officials said. Advertisement Giuseppe Santonocito, the 33-year-old owner of the seized food truck, and his three employees who allegedly made the tainted paninis are under investigation. Officials also ordered a nationwide seizure of the panini, which was commercially produced, and are probing other products sold at the truck. Santonocito purchased the produce used in the paninis in late July, and only had enough to make 'six or seven' sandwiches before they ran out, his lawyer told the outlet. Tamara D'Acunto, 45, died shortly after eating a panini purchased from a food truck in southwest Italy. Advertisement 'He is psychologically devastated. He has worked for around nine years in the food sector and he is well respected. He is convinced that the contamination was already in the products that he served,' his lawyer said. Five doctors who treated the victims at two different hospitals are also being probed for apparently not making their diagnoses quickly enough, officials said. Botulism, a bacterial infection, is most commonly linked to food poisoning, according to the Centers for Disease Control and Prevention. In extreme cases, it can cause muscle paralysis and even death. Advertisement In late July, another toxic botulism outbreak in Sardinia, an island west of Italy's mainland, left one woman dead after eating spoiled guacamole at a festival. Seven others, including an 11-year-old boy, were treated for food poisoning. Italy's Ministry of Health 'immediately activated all the health protocols' following the dual outbreaks to ensure 'that patients had timely access to life-saving antidote treatments,' according to the government agency.
